Physician profile
Amman Starr
NPI 1649450529
$573.28
in general payments reported to CMS, 2019-2025
13 companies · $51.37 in 2025
The $51.37 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.68 · 2020: $52.16 · 2021: $57.27 · 2022: $231 · 2023: $78.29 · 2024: $19.10 · 2025: $51.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $130.19 | 2019-2023 | Cequa |
| Alcon Vision LLC | $112.97 | 2019-2022 | |
| Notal Vision, INC. | $68.34 | 2022 | |
| Oyster Point Pharma, INC. | $67.56 | 2022-2023 | Tyrvaya |
| Biotissue Holdings INC. | $44.72 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $25.84 | 2025 | Xdemvy |
| Coopervision INC. | $25.53 | 2025 | Biofinity Contact Lens |
| Abbvie INC. | $22.36 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $19.49 | 2023 | Acuvue |
| Bausch & Lomb Americas INC. | $19.10 | 2024 | Infuse |
| Glaukos Corporation | $15.46 | 2022 | |
| Shire North American Group INC | $13.23 | 2019 | |
| Rxsight INC | $8.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amman Starr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.